Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

Benci, Joseph L., Xu, Bihui, Qiu, Yu, Wu, Tony J., Dada, Hannah, Twyman-Saint Victor, Christina, Cucolo, Lisa, Lee, David S.M. +11 more·2016·Cell
DOI 10.1016/j.cell.2016.11.022

Cited by (1,000)

Items 101–200 of 1,000

  1. Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy
    Mirjana Efremova, Francesca Finotello, Dietmar Rieder, Zlatko Trajanoski · 2017 · Frontiers in Immunology
  2. If we build it they will come: targeting the immune response to breast cancer
    Margaret Elena Gatti-Mays, Justin Micah Balko, Sofia R. Gameiro, Harry D. Bear, Sangeetha Prabhakaran, Jami Aya Fukui, Mary Lenora Disis, Rita Nanda, James L. Gulley, Kevin M. Kalinsky et al. · 2019 · npj Breast Cancer
  3. In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target
    Xiaoqing Wang, Collin J. Tokheim, Shengqing Stan Gu, Binbin Wang, Qin Tang, Yihao Li, Nicole C. Traugh, Zexian Zeng, Yi Zhang, Ziyi Li et al. · 2021 · Cell
  4. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
    Jaroslav Žák, Isaraphorn Pratumchai, Brett S. Marro, Kristi Marquardt, Reza Beheshti Zavareh, Luke L. Lairson, Michael B. A. Oldstone, Judith A. Varner, Livia T. Hegerova, Qing Cao et al. · 2024 · Science
  5. The Interferon-Gamma Paradox in Cancer
    M. Raza Zaidi · 2018 · Journal of Interferon & Cytokine Research
  6. The JAK/STAT3 axis: A comprehensive drug target for solid malignancies
    Jennifer Huynh, Nima Etemadi, Frédéric Hollande, Matthias Ernst, Michael Büchert · 2017 · Seminars in Cancer Biology
  7. Predictors of responses to immune checkpoint blockade in advanced melanoma
    Nicolas Jacquelot, María P. Roberti, David Pierre Enot, Sylvie Rusakiewicz, Nils Ternès, S. Jegou, David Michael Woods, Andressa L. Sodré, Morten Hansen, Yaron Meirow et al. · 2017 · Nature Communications
  8. LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy
    Gaopeng Li, Ilona Kryczek, Jutaek Nam, Xiong Li, Shasha Li, Jing Li, Shuang Wei, Sara Grove, Linda Vatan, Jiajia Zhou et al. · 2021 · Nature Cell Biology
  9. Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy
    Ma, Shijun, Zhao, Yue, Lee, Wee Chyan, Ong, Li-Teng, Lee, Puay Leng, Jiang, Zemin, Oguz, Gokce, Niu, Zhitong, Liu, Min, Goh, Jian Yuan et al. · 2022 · Nature Communications
  10. Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
    Zhengyi Wang, Xiaoying Wu · 2020 · Cancer Medicine
  11. Opposing Roles of Type I Interferons in Cancer Immunity
    Giselle M. Boukhaled, Shane M. Harding, David G. Brooks · 2020 · Annual Review of Pathology Mechanisms of Disease
  12. Resistance mechanisms to immune checkpoint inhibitors: updated insights
    Besan H. Al-Saafeen, Bassam R. Ali, Eyad Elkord · 2025 · Molecular Cancer
  13. Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance
    Young‐Jun Park, Da‐Sol Kuen, Yeonseok Chung · 2018 · Experimental & Molecular Medicine
  14. Defining and Understanding Adaptive Resistance in Cancer Immunotherapy
    Tae Kon Kim, Roy S. Herbst, Lieping Chen · 2018 · Trends in Immunology
  15. Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity
    NE Donlon, Robert F. Power, Conall Hayes, John Vincent Reynolds, Joanne Lysaght · 2021 · Cancer Letters
  16. The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function
    Lexus R. Johnson, Daniel Y. Lee, Jacqueline S. Eacret, Darwin Ye, Carl H. June, Andy J. Minn · 2021 · Cell
  17. GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment
    Marie Jo Halaby, Kebria Hezaveh, Sara Lamorte, M. Teresa Ciudad, Andreas Kloetgen, Bethany L. MacLeod, Mengdi Guo, Ankur Chakravarthy, Tiago da Silva Medina, Stefano Ugel et al. · 2019 · Science Immunology
  18. Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance
    Adnin Ashrafi, Zakia Akter, Pouya Modareszadeh, Parsa Modareszadeh, Eranda Berisha, Parinaz Sadat Alemi, Maria del Carmen Chacon Castro, Alexander R. Deese, Zhang Li · 2022 · Cancers
  19. Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy
    Ruan F.V. Medrano, Aline Hunger, Samir Andrade Mendonça, José Alexandre Marzagão Barbuto, Bryan Eric Strauss · 2017 · Oncotarget
  20. Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance
    Megha Budhwani, Roberta Mazzieri, Riccardo Dolcetti · 2018 · Frontiers in Oncology
  21. Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades
    Hao Chen, Wei Chong, Qian Wu, Yueliang Yao, Min Mao, Xin Wang · 2019 · Frontiers in Immunology
  22. Bioorthogonal Guided Activation of cGAS‐STING by AIE Photosensitizer Nanoparticles for Targeted Tumor Therapy and Imaging
    Minhui Cui, Dongsheng Tang, Bin Wang, Hanchen Zhang, Ganghao Liang, Haihua Xiao · 2023 · Advanced Materials
  23. Galectin-1–driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance
    Dhanya K. Nambiar, Todd Anthony Aguilera, Hongbin Cao, Shirley Kwok, Christina S. Kong, Joshua Daniel Bloomstein, Zemin Wang, Vangipuram S. Rangan, Dadi Jiang, Rie von Eyben et al. · 2019 · Journal of Clinical Investigation
  24. Dendritic cell maturation in cancer
    Chang Yoon Moon, Meriem Belabed, Matthew D. Park, Raphaël Mattiuz, Daniel J. Puleston, Miriam Mérad · 2025 · Nature reviews. Cancer
  25. Targeting TBK1 to overcome resistance to cancer immunotherapy
    Sun, Yi, Revach, Or-yam, Anderson, Seth, Kessler, Emily A., Wolfe, Clara H., Jenney, Anne, Mills, Caitlin E., Robitschek, Emily J., Davis, Thomas G. R., Kim, Sarah et al. · 2023 · Nature
  26. Reversing cold tumors to hot: An immunoadjuvant-functionalized metal-organic framework for multimodal imaging-guided synergistic photo-immunotherapy
    Zhijin Fan, Hongxing Liu, Yaohua Xue, Jingyan Lin, Yu Fu, Zhaohua Xia, Dong-ming Pan, Jian Zhang, Kun Qiao, Zhenzhen Zhang et al. · 2020 · Bioactive Materials
  27. T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy
    Yihui Zhai, Jinming Wang, Tianqun Lang, Ying Kong, Rong Rong, Ying Cai, Wei Ran, Fengqin Xiong, Chao Zheng, Yanke Wang et al. · 2021 · Nature Nanotechnology
  28. Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
    Knox, Tessa, Sahakian, Eva, Banik, Debarati, Hadley, Melissa, Palmer, Erica, Noonepalle, Satish, Kim, Jennifer, Powers, John, Gracia-Hernandez, Maria, Oliveira, Vasco et al. · 2019 · Scientific Reports
  29. Immune Landscape of Colorectal Cancer Tumor Microenvironment from Different Primary Tumor Location
    Longhui Zhang, Yuetao Zhao, Ying Dai, Jianan Cheng, Zhihua Gong, Yi Feng, Chengdu Sun, Qingzhu Jia, Bo Zhu · 2018 · Frontiers in Immunology
  30. Type I interferon signaling, regulation and gene stimulation in chronic virus infection
    Sabelo Lukhele, Giselle M. Boukhaled, David G. Brooks · 2019 · Seminars in Immunology
  31. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma
    Peng Zhang, Jason M. Miska, Catalina Lee-Chang, Aida Rashidi, Wojciech K. Panek, Shejuan An, Μαρκέλλα Ζαννίκου, Aurora Lopez‐Rosas, Yu Han, Ting Xiao et al. · 2019 · Proceedings of the National Academy of Sciences
  32. Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs
    Massimo Gadina, Catrina Johnson, Daniella M. Schwartz, Michael Markus Bonelli, Sarfaraz Hasni, Yuka Kanno, Paul S. Changelian, Arian D. J. Laurence, John J. O’Shea · 2018 · Journal of Leukocyte Biology
  33. Bystander IFN-γ activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment
    Ronan Thibaut, Pierre Bost, Idan Milo, Marine Cazaux, Fabrice Lemaı̂tre, Zacarias Garcia, Ido Amit, Béatrice Bréart, Clémence Cornuot, Benno Schwikowski et al. · 2020 · Nature Cancer
  34. Immunotherapy for Head and Neck Squamous Cell Carcinoma
    Jessica M. Moskovitz, Jennifer D. Moy, Robert Louis Ferris · 2018 · Current Oncology Reports
  35. Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
    Chunying Song, Marco Piva, Lu Sun, Aayoung Hong, Gatien Moriceau, Xiangju Kong, Hong Zhang, Shirley H. Lomeli, Jin Qian, Clarissa C. Yu et al. · 2017 · Cancer Discovery
  36. Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
    Jie Bai, Zhitao Gao, Xiang Li, Liang Dong, Weidong Han, Jing Nie · 2017 · Oncotarget
  37. MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy
    Julia Reinhardt, Jennifer Landsberg, Jonathan Leo Schmid-Burgk, Bartomeu Bibiloni Ramis, Tobias Bald, Nicole Glodde, Dorys Lopez-Ramos, Arabella Young, Shin Foong Ngiow, Daniel Nettersheim et al. · 2017 · Cancer Research
  38. Integration of radiotherapy and immunotherapy for treatment of oligometastases
    Sean P. Pitroda, Steven J. Chmura, Ralph R. Weichselbaum · 2019 · The Lancet Oncology
  39. IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting
    Kazuyoshi Takeda, M. NAKAYAMA, Yoshihiro Hayakawa, Yuko Kojima, Hiroaki Ikeda, Naoko Imai, Kouetsu Ogasawara, Ko Okumura, David Morgan Thomas, Mark John Smyth · 2017 · Nature Communications
  40. TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
    Jayakumar Narayanan Vadakekolathu, Catherine Lai, Stephen Reeder, SE Church, Tressa Hood, Anbarasu Lourdusamy, Michael P. Rettig, Ibrahim Taha Aldoss, Anjali S. Advani, John E. Godwin et al. · 2020 · Blood Advances
  41. Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy
    Gaopeng Li, Jae Eun Choi, Ilona Kryczek, Yilun Sun, Peng Liao, Shasha Li, Shuang Wei, Sara Grove, Linda Vatan, Reagan Nelson et al. · 2023 · Cancer Cell
  42. Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling
    Chuanhui Han, Zhida Liu, Yunjia Zhang, Aijun Shen, Chunbo Dong, Anli Zhang, Casey Moore, Zhenhua Ren, Changzheng Lu, Xuezhi Cao et al. · 2020 · Nature Immunology
  43. Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade
    Christopher A. Natale, Jinyang Li, Junqian Zhang, Ankit Dahal, Tzvete Dentchev, Ben Z. Stanger, Todd W. Ridky · 2018 · eLife
  44. The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
    Su Yin Lim, Elena Shklovskaya, Jenny Lee, Bernadette Pedersen, Ashleigh Stewart, Zizhen Ming, Mal Irvine, Brindha Shivalingam, Robyn P.M. Saw, Alexander Maxwell Menzies et al. · 2023 · Nature Communications
  45. Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
    Chia‐Lang Hsu, Da‐Liang Ou, Li‐Yuan Bai, Chia‐Wei Chen, Liang‐In Lin, Shiu-Feng Kathy Huang, Ann‐Lii Cheng, Yung‐Ming Jeng, Chiun Hsu · 2021 · Liver Cancer
  46. The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity
    Sangeetha S. Palakurthi, Mari Kuraguchi, Sima J. Zacharek, Enrique Zudaire, Wei Huang, Dennis M. Bonal, Jeffrey Liu, Abha Dhaneshwar, Kristin DePeaux, Martha R. Gowaski et al. · 2019 · Cancer Immunology Research
  47. Long-distance modulation of bystander tumor cells by CD8+ T-cell-secreted IFN-γ
    Mirjam E. Hoekstra, Laura Bornes, Feline E. Dijkgraaf, Daisy Philips, Iris N. Pardieck, Mireille Toebes, Daniela S. Thommen, Jacco van Rheenen, Ton N. Schumacher · 2020 · Nature Cancer
  48. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study
    Christine M. Bestvina, Kelli B. Pointer, Theodore G Karrison, Hania Al‐Hallaq, Philip C. Hoffman, Michael J. Jelinek, Aditya Juloori, J.M. Melotek, Septimiu Dan Murgu, J. Partouche et al. · 2021 · Journal of Thoracic Oncology
  49. The Promise of Combining Radiation Therapy With Immunotherapy
    Justin C. Jagodinsky, Paul M. Harari, Zachary Scott Morris · 2020 · International Journal of Radiation Oncology*Biology*Physics
  50. IFNγ signaling integrity in colorectal cancer immunity and immunotherapy
    Wan Du, Timothy L. Frankel, Michael Green, Weiping Zou · 2021 · Cellular and Molecular Immunology
  51. Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response
    Michelle von Locquenghien, Catalina Rozalén, Toni Celià-Terrassa · 2021 · Journal of Clinical Investigation
  52. Hallmarks of Resistance to Immune-Checkpoint Inhibitors
    Maria Karasarides, Alexandria P. Cogdill, Paul B. Robbins, Michaela Bowden, Elizabeth M. Burton, Lisa Helene Butterfield, Alessandra Cesano, Christian Hammer, Cara Haymaker, Christine E. Horak et al. · 2022 · Cancer Immunology Research
  53. Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC
    Evelyn M. Nguyen, Hirokazu Taniguchi, Joseph Minhow Chan, Yingqian Ada Zhan, Xiaoping Chen, Juan Jan Qiu, Elisa de Stanchina, Viola Allaj, Nisargbhai Shah, Fathema Z. Uddin et al. · 2022 · Journal of Thoracic Oncology
  54. USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity
    Xing Huang, Qi Zhang, Yu Lou, Junli Wang, Xinyu Zhao, Lin Wang, Xiaozhen Zhang, Shanshan Li, Yulan Zhao, Qi Chen et al. · 2019 · Cancer Immunology Research
  55. Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade
    Pai, Chien-Chun Steven, Huang, John T., Lu, Xiaoqing, Simons, Donald M., Park, Chanhyuk, Chang, Anthony, Tamaki, Whitney, Liu, Eric, Roybal, Kole T., Seagal, Jane et al. · 2019 · Immunity
  56. Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation
    Marie-Léa Gauci, Émilie Lanoy, Stéphane Champiat, Caroline Caramella, Samy Ammari, Sandrine Aspeslagh, Andréa Varga, Capucine Baldini, Rastilav Bahleda, Anas Gazzah et al. · 2018 · Clinical Cancer Research
  57. Type I and II Interferons in the Anti-Tumor Immune Response
    Sarah Elizabeth Fenton, Diana Saleiro, Leonidas C. Platanias · 2021 · Cancers
  58. Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy
    Jiashu Han, Mengwei Wu, Ziwen Liu · 2023 · Frontiers in Immunology
  59. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy
    Jeffrey C. Thompson, Wei‐Ting Hwang, Christiana W. Davis, Charuhas G. Deshpande, Seth Jeffries, Yashoda Rani Rajpurohit, Vinod Krishna, Denis S. Smirnov, Raluca I. Verona, Matthew V. Lorenzi et al. · 2019 · Lung Cancer
  60. Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression
    Julian Philipp Layer, Marie Kronmüller, Thomas Quast, Debby Konijnenberg, Maike Effern, Daniel Hinze, Kristina Althoff, Alexander R. Schramm, Frank Westermann, Martin Peifer et al. · 2017 · OncoImmunology
  61. CD4+ T cells in antitumor immunity
    Elena I Montauti, David Yoonsuk Oh, Lawrence H. Fong · 2024 · Trends in cancer
  62. Immune checkpoint blockade therapy
    Thomas Wieder, Thomas Eigentler, Ellen Brenner, Martin Röcken · 2018 · Journal of Allergy and Clinical Immunology
  63. ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity
    Matthew B. Maxwell, Marianne S. Hom, Jawoon Yi, Shitian Li, Samuel A. Rivera, Jingting Yu, Mannix J. Burns, Helen M. McRae, Braden T. Stevenson, Katherine E. Coakley et al. · 2024 · Cell
  64. Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma
    Anusha K. Kalbasi, Mito Tariveranmoshabad, Kevin N. Hakimi, Sarah V. Kremer, Katie Marie Campbell, Juan Manuel Funes, Agustin Vega-Crespo, Giulia Parisi, Ameya S. Champhekar, Christine Nguyen et al. · 2020 · Science Translational Medicine
  65. Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes
    Yangzhi Qi, Baohui Liu, Qian Sun, Xiaoxing Xiong, Qianxue Chen · 2020 · Frontiers in Immunology
  66. Mechanisms of Resistance to Immune Checkpoint Blockade
    David Liu, Russell William Jenkins, Ryan Joseph Sullivan · 2018 · American Journal of Clinical Dermatology
  67. Spatial and Temporal Mapping of Breast Cancer Lung Metastases Identify TREM2 Macrophages as Regulators of the Metastatic Boundary
    Yofe, Ido, Shami, Tamar, Cohen, Noam, Landsberger, Tomer, Sheban, Fadi, Stoler-Barak, Liat, Yalin, Adam, Phan, Truong San, Li, Baoguo, Monteran, Lea et al. · 2023 · Cancer Discovery
  68. Type I Interferons and Cancer: An Evolving Story Demanding Novel Clinical Applications
    Eleonora Aricò, Luciano Castiello, Imerio Capone, Lucia Gabriele, Filippo Belardelli · 2019 · Cancers
  69. Engineering interferons and interleukins for cancer immunotherapy
    Patrick G. Holder, Shion An Lim, Christine Huang, Preeti Apurve Sharma, Yavuz S. Dagdas, Beyza Bulutoglu, Jonathan T. Sockolosky · 2022 · Advanced Drug Delivery Reviews
  70. Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment
    Laurel B. Darragh, Ayman J. Oweida, Sana D. Karam · 2019 · Frontiers in Immunology
  71. Type I IFN protects cancer cells from CD8+ T cell–mediated cytotoxicity after radiation
    Jianzhou Chen, Yunhong Cao, Boštjan Markelc, Jakob Kaeppler, Jenny A. F. Vermeer, Ruth J. Muschel · 2019 · Journal of Clinical Investigation
  72. Type I interferons in host defence and inflammatory diseases
    Mary K. Crow, Lars Rönnblom · 2019 · Lupus Science & Medicine
  73. IFN-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression
    Hussein F. Aqbi, Matthew Wallace, Samay Sappal, Kyle K. Payne, Masoud H. Manjili · 2018 · Journal of Leukocyte Biology
  74. Disrupting the phase separation of KAT8–IRF1 diminishes PD-L1 expression and promotes antitumor immunity
    Yuanzhong Wu, Liwen Zhou, Yezi Zou, Yijun Zhang, Meifang Zhang, Liping Xu, Lisi Zheng, Wenting He, Kuai Yu, Ting Li et al. · 2023 · Nature Cancer
  75. Immunosurveillance in clinical cancer management
    Guido Kroemer, Timothy An-thy Chan, Alexander M.M. Eggermont, Lorenzo Galluzzi · 2023 · CA A Cancer Journal for Clinicians
  76. Aggressive PDACs Show Hypomethylation of Repetitive Elements and the Execution of an Intrinsic IFN Program Linked to a Ductal Cell of Origin
    Elisa Espinet, Zuguang Gu, Charles David Imbusch, Nathalia A. Giese, Magdalena Büscher, Mariam Safavi, Silke Weisenburger, Corinna Klein, Vanessa Vogel, Mattia Falcone et al. · 2020 · Cancer Discovery
  77. Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
    Sara Saab, Hussein Zalzale, Zahraa Rahal, Yara Khalifeh, Ansam F. Sinjab, Humam N. Kadara · 2020 · Frontiers in Immunology
  78. Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance
    Rik Jasper Verheijden, Mick J M van Eijs, Anne Maria May, Femke van Wijk, Karijn P.M. Suijkerbuijk · 2023 · npj Precision Oncology
  79. Recent advances in the clinical development of immune checkpoint blockade therapy
    Atefeh Ghahremanloo, Arash Soltani, Seyed Mohamad Sadegh Modaresi, Seyed Isaac Hashemy · 2019 · Cellular Oncology
  80. Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
    Dimitrios C. Ziogas, Charalampos Theocharopoulos, Tilemachos Koutouratsas, John B.A.G. Haanen, Helen J Gogas · 2022 · Cancer Treatment Reviews
  81. Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy
    Erez N. Baruch, Frederico O. Gleber‐Netto, Priyadharsini Nagarajan, Xiayu Rao, Shamima Akhter, Tuany Eichwald, Tongxin Xie, Mohammad Balood, Adebayo Adewale, Shorook Na’ara et al. · 2025 · Nature
  82. Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma
    Rui-Yan Wu, Pengfei Kong, Liang-Ping Xia, Yun Huang, Zhi‐Ling Li, Yun-Yun Tang, Yu-Hong Chen, Xuan Li, Ravichandran Senthilkumar, Hai‐Liang Zhang et al. · 2019 · Clinical Cancer Research
  83. Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
    Tessa J. Knox, Eva Sahakian, Debarati Banik, Melissa M. Hadley, Erica Palmer, Satish Kumar Reddy Noonepalle, Jennifer S. Kim, John Joseph Powers, Maria Gracia-Hernandez, Vasco A. Oliveira et al. · 2019 · Scientific Reports
  84. Senescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironment
    Damien Maggiorani, Oanh Lê, Véronique Lisi, Séverine Landais, Gaël Moquin‐Beaudry, Vincent‐Philippe Lavallée, Hélène Decaluwe, Christian M. Beausejour · 2024 · Nature Communications
  85. Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways
    Bai, Xue, Fisher, David E., Flaherty, Keith T. · 2019 · Nature Reviews Clinical Oncology
  86. The role of N6-methyladenosine mRNA in the tumor microenvironment
    Min Li, Xuan Zha, Shengjun Wang · 2021 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  87. Cell cycle checkpoints cooperate to suppress DNA- and RNA-associated molecular pattern recognition and anti-tumor immune responses
    Chen, Jie, Harding, Shane M., Natesan, Ramakrishnan, Tian, Lei, Benci, Joseph L., Li, Weihua, Minn, Andy J., Asangani, Irfan A., Greenberg, Roger A. · 2020 · Cell Reports
  88. Characterizing Macrophage Diversity in Metastasis-Bearing Lungs Reveals a Lipid-Associated Macrophage Subset
    Danielle N. Huggins, Rebecca S. LaRue, Ying Wang, Todd Philip Knutson, Yingzheng Xu, Jesse W. Williams, Kathryn L. Schwertfeger · 2021 · Cancer Research
  89. Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction
    Jingya Qiu, Bihui Xu, Darwin Ye, Diqiu Ren, Shangshang Wang, Joseph L. Benci, Yuanming Xu, Hemant Ishwaran, Jean‐Christophe Beltra, E. John Wherry et al. · 2023 · Nature Cancer
  90. LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity
    Shin Foong Ngiow, Sasikanth Manne, Yinghui Huang, Tarek Azar, Zeyu Chen, Divij Mathew, Qingzhou Chen, Omar Khan, Jennifer E. Wu, Víctor Alcalde et al. · 2024 · Cell
  91. Dichloroacetate restores colorectal cancer chemosensitivity through the p53/miR-149-3p/PDK2-mediated glucose metabolic pathway
    Yu Liang, Lidan Hou, Linjing Li, Lei Li, Liming Zhu, Yu Wang, Xin Yi Huang, Yichao Hou, Danxi Zhu, Huimin Zou et al. · 2019 · Oncogene
  92. A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
    Umair Mahmood, Andrew Bang, Yu‐Hui Chen, Raymond H. Mak, Jochen H. Lorch, Glenn J. Hanna, Mizuki Nishino, Claire Manuszak, Emily M. Thrash, Mariano Severgnini et al. · 2020 · International Journal of Radiation Oncology*Biology*Physics
  93. Mechanisms of Tumor Cell–Intrinsic Immune Evasion
    Stefani Spranger, Thomas Frank Gajewski · 2017 · Annual Review of Cancer Biology
  94. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
    Carmine De Angelis, Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan, Sarmistha Nanda, Lanfang Qin, Vidyalakshmi Sethunath, Tao Wang et al. · 2021 · Clinical Cancer Research
  95. A Checkpoint‐Regulatable Immune Niche Created by Injectable Hydrogel for Tumor Therapy
    Qian Li, Zhipeng Zhao, Xiaohan Qin, Mengzhu Zhang, Qian Du, Zhonghao Li, Yuxia Luan · 2021 · Advanced Functional Materials
  96. JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance
    Hatem E. Sabaawy, Bríd M. Ryan, Hossein Khiabanian, Sharon R. Pine · 2021 · Carcinogenesis
  97. Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy
    Imerio Capone, Paolo Marchetti, Paolo A. Ascierto, Walter Malorni, Lucia Gabriele · 2018 · Frontiers in Immunology
  98. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models
    Manish Ramesh Patel, Alexander Dash, Blake A. Jacobson, Yan Ji, Daniel C. Baumann, Kareem Ismail, Robert Arthur Kratzke · 2019 · Cancer Gene Therapy
  99. Dendritic cell paucity in mismatch repair–proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy
    William W. Ho, Igor Lucas Gomes-Santos, Shuichi Aoki, Meenal Datta, Kosuke Kawaguchi, Nilesh P. Talele, Sylvie Roberge, Jun P. Ren, Hao Liu, Ivy X. Chen et al. · 2021 · Proceedings of the National Academy of Sciences
  100. The interferon-stimulated gene RIPK1 regulates cancer cell intrinsic and extrinsic resistance to immune checkpoint blockade
    Lisa Cucolo, Qingzhou Chen, Jingya Qiu, Yongjun Yu, Max Klapholz, Krista A. Budinich, Zhaojun Zhang, Yue Shao, Igor E. Brodsky, Martha S. Jordan et al. · 2022 · Immunity